Article
ConcertAI hits $1.9B valuation with $150M series C for real-world data cancer research tools
Rating:
0.0
Views:
89
Likes:
1
Library:
1
ConcertAI is now valued at $1.9 billion after banking a $150 million series C round to scale its software and real-world data (RWD) solutions for cancer research. | ConcertAI, formerly Concerto HealthAI, grabbed $150 million in a series C round that boosted the startup to a $1.9 billion valuation. The company develops software that marries AI and real-world data to accelerate cancer research.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value